Contract Pharma2h
FDA Approves Celltrion’s Biosimilar to ACTEMRA
The U.S. Food and Drug Administration (FDA) has approved Celltrion’s AVTOZMA (CT-P47, tocilizumab-anoh) in both an ...
centerforbiosimilars1h
FDA Approves Celltrion's Avtozma as Third Tocilizumab Biosimilar
The FDA approved Avtozma, a tocilizumab biosimilar developed by Celltrion, for the treatment of several rheumatic conditions.
Medscape6d
Tocilizumab: The First Interleukin-6-Receptor Inhibitor
Purpose: The pharmacology, pharmacokinetics, clinical efficacy, safety, and role of tocilizumab in rheumatoid arthritis (RA) are reviewed. Summary: Tocilizumab is a novel monoclonal antibody that ...
PipelineReview.com8h
U.S. FDA approves Celltrion’s AVTOZMA® (tocilizumab-anoh), a biosimilar to ACTEMRA®
JERSEY CITY, NJ, USA I January 30, 2025 I Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA® (CT-P47, ...
The American Journal of Managed Care9d
Study of Prophylactic Tocilizumab May Soon Add Talquetamab Arm
Prophylactic tocilizumab has the potential to decrease cytokine release syndrome and neurotoxicity for bispecific antibodies, explained Robert Rifkin, MD, FACP, a medical oncologist and ...